Radiotherapy for Anal Cancer: Intensity-Modulated Radiotherapy and Future Directions.

[1]  R. James.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin , 1996, The Lancet.

[2]  Charles R. Thomas,et al.  Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Ashesh B Jani,et al.  Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. , 2005, International journal of radiation oncology, biology, physics.

[4]  Branislav Jeremic,et al.  Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature. , 2015, Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology.

[5]  J. Roeske,et al.  Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[6]  J. Pignon,et al.  Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  T. Conroy,et al.  Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Castro,et al.  Phase 1 study of cetuximab in combination with 5‐fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma , 2013, Cancer.

[9]  I. El Naqa,et al.  Elective Clinical Target Volumes for Conformal Therapy in Anorectal Cancer: An RTOG Consensus Panel Contouring Atlas , 2008 .

[10]  J. Schellens,et al.  Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study. , 2013, International journal of radiation oncology, biology, physics.

[11]  P. Catalano,et al.  Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results. , 2012 .

[12]  J. Ledermann,et al.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. , 2013, The Lancet. Oncology.

[13]  Yi-Jen Chen,et al.  Organ sparing by conformal avoidance intensity modulated radiation therapy for anal cancer: Dosimetric evaluation of coverage of pelvis and inguinal/femoral nodes , 2005 .

[14]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[15]  P. Sharma,et al.  NCI9673: A multi-institutional eETCTN phase II study of nivolumab in refractory metastatic squamous cell carcinoma of the anal canal (SCCA). , 2016 .

[16]  R. Muirhead,et al.  Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[17]  R. Muirhead,et al.  Stepwise Multicenter Introduction of Intensity Modulated Radiation Therapy for Anal Cancer in the United Kingdom: From Consensus Guidance to Large-Scale Prospective Audit, Prior to Future Clinical Trials , 2016 .

[18]  H. Bartelink,et al.  Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Willett,et al.  Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. , 2008, International journal of radiation oncology, biology, physics.

[20]  P. Parikh,et al.  Two-year outcomes of RTOG 0529: A phase II evaluation of dose-painted IMRT in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Issam El Naqa,et al.  Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. , 2009, International journal of radiation oncology, biology, physics.

[22]  V. Vaitkevicius,et al.  Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal , 1981, Cancer.

[23]  N. Petrelli,et al.  Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Jacqueline Esthappan,et al.  RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. , 2013, International journal of radiation oncology, biology, physics.

[25]  M. Plummer,et al.  Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. , 2012, The Lancet. Oncology.

[26]  C. E,et al.  Radical radiotherapy for cervix cancer: the effect of waiting time on outcome. , 2005, International journal of radiation oncology, biology, physics.

[27]  Charles R. Thomas,et al.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. , 2008, JAMA.